← All trials
NCT06164951
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 10, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Apr 30, 2026
- First posted
- Dec 11, 2023
- Last posted
- Dec 21, 2023
- Enrollment
- 110
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- QED Therapeutics, Inc.Lead sponsor
- QED Therapeutics, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.